Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program

To assess cardiac toxicity by echocardiography

Number of cardiovascular events registered in a diary

To assess cardiac function by a Holter

To assess cardiac autonomic system balance by a Holter

To assess muscle mass loss by Inbody

With the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0. It is used to asses quality of life. It contains 30 items with both multi-item scales and single-item measures. Values are assigned between 1 and 4 (1: not at all, 2: a little, 3: enough, 4: a lot) according to the patient's responses to the item, only in items 29 and 30 evaluate with a score of 1 to 7 (1: lousy, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of cancer impact on the patient of each of the scales. The high values in the scales of global health and function state indicate a better CV, while in the scale of symptoms it would indicate a decrease in CV since it indicates the presence of symptoms associated with cancer.

European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). It is a breast cancer module of EORTC QLQ-C30. This module contains 23 items assessing symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. After the scoring procedures for the QLQ-C30, all scale and single-item scores are linearly transformed to a 0 to 100 scale. For the functional scales and single items (ie, body image, sexuality, and future perspective), higher scores represent a better level of functioning. For the symptom scales and single item, a higher score represents a higher level of symptoms.

type of chemotherapy agent used and number of sessions.

delay of doses or reduction, total doses received from the total expected.

Patient stopped receiving chemotherapy before last >=1 sessions.

Adverse effects of chemotherapy treatment and if it was interrupted (>=3 missing consecutive bouts of exercise)

>=1 bout that required a dose modification during the program and number of bouts modified in total.

days from the start to the end of chemotherapy, if it was terminated for toxicity and/or tumor progression.

Frequency of serious and non-serious events occurring during program.

assessed by the 6-Minute Walking Test

assessed by a digital dynamometer: TKK 5101 Grip-D; Takey, Tokyo, Japan

assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)

assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)

assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)

assessed by the Modified sit-and-reach test

assessed by an inelastic tape

assessed by the InBody

Thiobarbituric acid reactive substances (TBARS)

carbonyls and 8-hydroxy-2' -deoxyguanosine (8-OHdG)

Number of lymphocytes: (cluster of differentiation (CD) 8 and 4 and regulatory T lymphocytes)

C-reactive protein (CRP)

interleukin (IL) 6 and 10

tumor necrosis factor (TNF) alpha

insulin-like growth factor 1 (IGF-1)